BURLINGAME, Calif.--(BUSINESS WIRE)--Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines and immunotherapeutics for infectious diseases and cancer, today announced results demonstrating that its universal influenza vaccine produces robust antibody responses and complete protection in H1N1 and H3N2 pre-clinical challenge models. A universal vaccine would protect against both epidemic virus strains mismatched with the annual seasonal vaccine and new pandemic threats like the H1N1 swine flu and could be stockpiled. Data on Juvaris’ vaccine platform will be presented at the 96th Annual Meeting of the American Association of Immunologists (AAI) taking place May 7-12, 2009 in Seattle, Wash.
